Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.
Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore 169857, Singapore.
Sci Transl Med. 2023 Jul 12;15(704):eadh3067. doi: 10.1126/scitranslmed.adh3067.
The quest for an effective dengue vaccine has culminated in two approved vaccines and another that has completed phase 3 clinical trials. However, shortcomings exist in each, suggesting that the knowledge on dengue immunity used to develop these vaccines was incomplete. Vaccine trial findings could refine our understanding of dengue immunity, because these are experimentally derived, placebo-controlled data. Results from these trials suggest that neutralizing antibody titers alone are insufficient to inform protection against symptomatic infection, implicating a role for cellular immunity in protection. These findings have relevance for both future dengue vaccine development and application of current vaccines for maximal public health benefit.
寻找有效的登革热疫苗已取得两项已批准的疫苗和另一项已完成 3 期临床试验的成果。然而，每种疫苗都存在缺陷，这表明用于开发这些疫苗的登革热免疫知识并不完整。疫苗试验结果可以完善我们对登革热免疫的认识，因为这些结果是通过实验获得的、安慰剂对照数据。这些试验的结果表明，单独的中和抗体滴度不足以提供对症状感染的保护，这暗示了细胞免疫在保护中的作用。这些发现对于未来的登革热疫苗开发以及为了实现最大公共卫生效益而应用当前疫苗都具有相关性。
